2009 drug utilization and cost trends: Tumor necrosis factor inhibitors

American Journal of Pharmacy Benefits

Volumn 2, Issue 6, 2010, Pages 387-392

  Theodorou, Anna A ^a   Johnson, Kelly M ^a   Szychowski, John A ^a  

^a CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BETA1A INTERFERON; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENZYME INHIBITOR; ERLOTINIB; ETANERCEPT; GLATIRAMER; GOLIMUMAB; IMATINIB; INFLIXIMAB; LEFLUNOMIDE; LENALIDOMIDE; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ANEMIA; ARTICLE; CROHN DISEASE; DATA BASE; DRUG COST; DRUG INDICATION; DRUG UTILIZATION; HUMAN; MONOTHERAPY; MULTIPLE SCLEROSIS; NEOPLASM; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

EID: 78751485920     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gatyas G. IMS Health reports U.S. prescription sales grew 5.1 percent in 2009 to $300.3 billion. April 1, 2010. http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=d690a27e9d5b7210VgnVCM100000ed152ca2RCRD&vgnextfmt=default. Accessed August 23, 2010.
2. Theodorou AA, Johnson KM, Ruf S, Szychowski JA. Prescription utilization by multiple sclerosis patients in the United States. Am J Pharm Benefits. 2010;2(2): 147-151.
3. Theodorou AA, Johnson KM, Wade T. Antineoplastic enzyme inhibitor drug trend utilization in the United States. Am J Pharm Benefits. 2010;2(3):231-234.
4. American College of Rheumatology. Rheumatoid arthritis. http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.asp. Accessed August 23, 2010.
5. Foundation of America. About Crohn's disease. http://www.ccfa.org/info/about/crohns. Accessed April 7, 2010.
6. American Academy of Dermatology. Psoriasis. http://www.aad.org/media/background/factsheets/fact_psoriasis.html. Accessed April 7, 2010.
7. The National Institute of Arthritis and Musculoskeletal and Skin Diseases. Arthritis. Questions and answers about arthritis and rheumatic diseases. http://www.niams.nih.gov/Health_Info/Arthritis/arthritis_rheumatic_qa.asp. Accessed August 23, 2010.
8. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoarthritis. http://www.niams.nih.gov/Health_Info/Osteoarthritis/default.asp#2. Accessed August 24, 2010.
9. US Food and Drug Administration. FDA: cancer warnings required for TNF Blockers. Press release. August 4, 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm. Accessed September 8, 2010.
10. Senior M. Just-approved Cimzia set to enter tough RA market. The Pink Sheet. May 14, 2009.
11. Merrill J. Three's a crowd: Cimzia joins Humira, Remicade for Crohn's disease. The Pink Sheet. May 5, 2008.
12. Abbott Laboratories. Abbott reports double-digit sales and earnings growth in fourth quarter; confirms strong outlook for 2009 earnings. Press release. January 21, 2009. http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0816.htm. Accessed June 23, 2010.
13. American College of Rheumatology. Practice management. Rheumatoid arthritis. http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.asp. Accessed April 7, 2010.
14. Splete H. TNF inhibitor significantly slows RA progression. Health News Daily. June 22, 2010.
15. Worcester S. TNF-blockers prevent RA progression in some large, weightbearing joints. Health News Daily. June 23, 2010.
16. Commercial Insight: Disease Modification in Rheumatoid Arthritis. DMHC 2448. New York: Datamonitor; January 2009:32.
17. Better treatment found for Crohn's disease. http://news.health.com/2010/04/14/better-treatment-found-crohns-disease/. Accessed September 8, 2010.
18. Taylor L. Gastroenterologists prescribing Humira off-label for ulcerative colitis. PharmaTimes. August 9, 2010.
19. Haas J. With strong Humira sales growth, Abbott is bullish on its second quarter results. The Pink Sheet. July 15, 2009.
20. Diller W. Market snapshot: anti-TNFs grow despite tough market. The Pink Sheet. December 8, 2008;70(049):18.
21. Generic Pharmaceutical Association. Economic analysis of generic pharmaceuticals 1999-2008: $734 billion in health care savings. May 2009:10-11.
22. Generic Pharmaceutical Association. Economic analysis of generic pharmaceuticals 1999-2008: $734 billion in health care savings. May 2009:11.
23. Japsen B. Hospira to test generic anemia drug. Chicago Tribune. July 28, 2010.
24. US National Library of Medicine. About DailyMed. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed August 24, 2010.